Randomization, Blinding and Placebo: Why Trials Are Built This Way

The problem these tools solve

If you give a new treatment to some people and nothing to others, the groups may differ in ways that have nothing to do with the treatment: age, severity, expectations, how closely they are watched. A trial is designed to make the comparison fair. Three tools do most of the work: randomization, blinding and a placebo or other comparator. This page explains each in plain language. It is education, not medical advice, and it does not tell anyone to join, avoid or stop any treatment.

Randomization: assigning by chance

In a randomized trial, an allocation sequence is generated by a process that includes an element of chance, and it decides who gets which intervention [1]. The point is that, on average, each group then has the same prognosis before treatment begins [1]. Without it, treatment choices in ordinary care are often influenced by prognostic factors, and that mix-up is called confounding [1]. This is why a trial can say more about cause and effect than a comparison of people who chose different treatments. See Observational Studies and Confounding.

Patients in trials often describe this as being assigned by chance to a treatment group or a control group [2].

Allocation concealment: not knowing the next assignment

Randomization only works if people cannot predict or steer who gets what. Allocation concealment means preventing participants and trial staff from knowing forthcoming assignments until after enrolment is confirmed; if staff can see the next assignment, they can steer certain people toward or away from a group [1]. The Cochrane Handbook stresses that this is different from blinding: concealment prevents bias in assignment and can always be done, while blinding prevents bias after assignment and cannot always be done, for example in trials comparing surgery with non-surgical care [1].

Blinding: not knowing who got what

Blinding (also called masking) means participants, the people delivering the intervention and often the people measuring the outcome do not know which group a participant is in. Lack of blinding can cause bias if it leads to changes in behavior; for example, low expectations in the comparison group may lead participants to seek the experimental treatment elsewhere [1]. Blinding does not always hold: in many drug trials, side effects can let some participants work out what they received, unless the trial compares similar interventions or uses an active placebo (a comparator designed to cause similar side effects) [1].

Placebo: a fair comparison, and its own effects

The NIH describes a placebo as an inactive substance that looks like the treatment being tested, and calls the "randomized, placebo-controlled" trial the "gold standard" design for testing interventions in people [3]. The placebo effect is a beneficial outcome that comes from a person's anticipation that an intervention will help, and the way a clinician interacts with a patient can also help independently of the treatment [3].

How large is it? A Cochrane review compared placebo with no treatment in 234 trials (outcome data were available for 202) across 60 conditions. Risk of bias was low in only 16 of those trials (8%). It found no important clinical effects of placebo in general. For trials with yes-or-no outcomes the pooled relative risk was 0.93 (95% confidence interval 0.88 to 0.99), and for continuous outcomes the standardized effect was small, -0.23 (95% CI -0.28 to -0.17) [4]. The authors found that placebo may influence patient-reported outcomes, especially pain and nausea, but that it is difficult to distinguish this from biased reporting [4]. The effect on pain varied from negligible to clinically important, even among low-risk-of-bias trials [4].

The practical lesson: a placebo group tells you what happens without the active ingredient, under the same expectations. The improvement in a placebo group is not proof that placebos heal.

What happens when these steps are missing

A combined analysis of 1,973 trials in 234 meta-analyses compared trials with and without these protections [5]:

These are averages across many trials, not a verdict on any one trial.

Quick checklist for a trial report

1. Was assignment random, and was the next assignment hidden from staff?
2. Who was blinded: participants, clinicians, outcome assessors?
3. What was the comparator: placebo, usual care, another active treatment?
4. Were the outcomes subjective (ratings) or objective?
5. How many people were in each group, and who dropped out?

Researchers also decide in advance whether there will be a control group and other ways to limit bias [6]. Learn about reading results in Effect Sizes and Confidence Intervals in Plain Language, and see how these ideas apply to one field in How to Read a Psychedelic Clinical Trial.